|
1
|
Pizzato M, Li M, Vignat J, Laversanne M,
Singh D, La Vecchia C and Vaccarella S: The epidemiological
landscape of thyroid cancer worldwide: GLOBOCAN estimates for
incidence and mortality rates in 2020. Lancet Diabetes Endocrinol.
10:264–272. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Seib CD and Sosa JA: Evolving
understanding of the epidemiology of thyroid cancer. Endocrinol
Metab Clin North Am. 48:23–35. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kitahara CM and Sosa JA: The changing
incidence of thyroid cancer. Nat Rev Endocrinol. 12:646–653. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ruiz FJ, Inkman M, Rashmi R, Muhammad N,
Gabriel N, Miller CA, McLellan MD, Goldstein M, Markovina S,
Grigsby PW, et al: HPV transcript expression affects cervical
cancer response to chemoradiation. JCI Insight. 6:e1387342021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ruiz FJ, Sundaresan A, Zhang J, Pedamallu
CS, Halle MK, Srinivasasainagendra V, Zhang J, Muhammad N, Stanley
J, Markovina S, et al: Genomic characterization and therapeutic
targeting of HPV undetected cervical carcinomas. Cancers (Basel).
13:45512021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
WHO Classification of Tumors Editorial
Board, . Endocrine tumors. 5th edition. IARC; Lyon: 2022
|
|
7
|
Ito Y, Miyauchi A and Oda H: Low-risk
papillary microcarcinoma of the thyroid: A review of active
surveillance trials. Eur J Surg Oncol. 44:307–315. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sugitani I, Ito Y, Miyauchi A, Imai T and
Suzuki S: Active surveillance versus immediate surgery:
Questionnaire survey on the current treatment strategy for adult
patients with low-risk papillary thyroid microcarcinoma in Japan.
Thyroid. 29:1563–1571. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Omry-Orbach G: Risk stratification in
differentiated thyroid cancer: An ongoing process. Rambam
Maimonides Med J. 7:e00032016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xing M, Haugen BR and Schlumberger M:
Progress in molecular-based management of differentiated thyroid
cancer. Lancet. 381:1058–1069. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu X, Bishop J, Shan Y, Pai S, Liu D,
Murugan AK, Sun H, El-Naggar AK and Xing M: Highly prevalent TERT
promoter mutations in aggressive thyroid cancers. Endocr Relat
Cancer. 20:603–610. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang N, Liu T, Sofiadis A, Juhlin CC,
Zedenius J, Höög A, Larsson C and Xu D: Tert promoter mutation as
an early genetic event activating telomerase in follicular thyroid
adenoma (FTA) and atypical FTA. Cancer. 120:2965–2979. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu R and Xing M: TERT promoter mutations
in thyroid cancer. Endocr Relat Cancer. 23:R143–R155. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu R, Bishop J, Zhu G, Zhang T, Ladenson
PW and Xing M: Mortality risk stratification by combining BRAF
V600E and TERT promoter mutations in papillary thyroid cancer:
Genetic duet of BRAF and TERT promoter mutations in thyroid cancer
mortality. JAMA Oncol. 3:202–208. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moon S, Song YS, Kim YA, Lim JA, Cho SW,
Moon JH, Hahn S, Park DJ and Park YJ: Effects of coexistent
BRAFV600E and TERT promoter mutations on poor clinical
outcomes in papillary thyroid cancer: A meta-analysis. Thyroid.
27:651–660. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bullock M, Ren Y, O'Neill C, Gill A, Aniss
A, Sywak M, Sidhu S, Delbridge L, Learoyd D, de Vathaire F, et al:
TERT promoter mutations are a major indicator of recurrence and
death due to papillary thyroid carcinomas. Clin Endocrinol (Oxf).
13:e01915602016.
|
|
17
|
Chung JH: BRAF and TERT promoter
mutations: Clinical application in thyroid cancer. Endocr J.
67:577–584. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G,
Murugan AK, Guan H, Yu H, Wang Y, et al: TERT promoter mutations
and their association with BRAF V600E mutation and aggressive
clinicopathological characteristics of thyroid cancer. J Clin
Endocrinol Metab. 99:E1130–E1136. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Staubitz JI, Müller C, Heymans A, Merten
C, Roos B, Poplawski A, Ludt A, Strobl S, Springer E, Schad A, et
al: Approach to risk stratification for papillary thyroid carcinoma
based on molecular profiling: Institutional analysis. BJS Open.
7:zrad0292023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McKelvey BA, Umbricht CB and Zeiger MA:
Telomerase reverse transcriptase (TERT) regulation in thyroid
cancer: A review. Front Endocrinol (Lausanne). 11:4852020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chiba K, Lorbeer FK, Shain AH, McSwiggen
DT, Schruf E, Oh A, Ryu J, Darzacq X, Bastian BC and Hockemeyer D:
Mutations in the promoter of the telomerase gene TERT contribute to
tumorigenesis by a two-step mechanism. Science. 357:1416–1420.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Z, Wang T, Wu Z, Zhang K, Li W, Yang
J, Chen C, Chen L and Xing J: Association between TERT rs2853669
polymorphism and cancer risk: A meta-analysis of 9,157 cases and
11,073 controls. PLoS One. 13:e01915602018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shen N, Lu Y, Wang X, Peng J, Zhu Y and
Cheng L: Association between rs2853669 in TERT gene and the risk
and prognosis of human cancer: A systematic review and
meta-analysis. Oncotarget. 8:50864–50872. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yoo SS, Do SK, Choi JE, Lee SY, Lee J, Cha
SI, Kim CH and Park JY: TERT polymorphism rs2853669 influences on
lung cancer risk in the Korean population. J Korean Med Sci.
30:1423–1428. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nencha U, Rahimian A, Giry M, Sechi A,
Mokhtari K, Polivka M, Schmitt Y, Di Stefano AL, Alentorn A,
Labussière M and Sanson M: TERT promoter mutations and rs2853669
polymorphism: Prognostic impact and interactions with common
alterations in glioblastomas. J Neurooncol. 126:441–446. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mosrati MA, Willander K, Falk IJ,
Hermanson M, Höglund M, Stockelberg D, Wei Y, Lotfi K and
Söderkvist P: Association between TERT promoter polymorphisms and
acute myeloid leukemia risk and prognosis. Oncotarget.
6:25109–25120. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ko E, Seo HW, Jung ES, Kim BH and Jung G:
The TERT promoter SNP rs2853669 decreases E2F1 transcription factor
binding and increases mortality and recurrence risks in liver
cancer. Oncotarget. 7:684–699. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Powter B, Jeffreys SA, Sareen H, Cooper A,
Brungs D, Po J, Roberts T, Koh ES, Scott KF, Sajinovic M, et al:
Human tert promoter mutations as a prognostic biomarker in glioma.
J Cancer Res Clin Oncol. 147:1007–1017. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vinothkumar V, Arun K, Arunkumar G,
Revathidevi S, Ramani R, Bhaskar LVKS, Murugan AK and Munirajan AK:
Association between functional tert promoter polymorphism rs2853669
and cervical cancer risk in south Indian women. Mol Clin Oncol.
12:485–494. 2020.PubMed/NCBI
|
|
30
|
Giunco S, Boscolo-Rizzo P, Rampazzo E,
Tirelli G, Alessandrini L, Di Carlo R, Rossi M, Nicolai P,
Menegaldo A, Carraro V, et al: Tert promoter mutations and
rs2853669 polymorphism: useful markers for clinical outcome
stratification of patients with oral cavity squamous cell
carcinoma. Front Oncol. 11:7826582021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hirokawa T, Arimasu Y, Chiba T, Nakazato
Y, Fujiwara M and Kamma H: Regulatory single nucleotide
polymorphism increases TERT promoter activity in thyroid carcinoma
cells. Pathobiology. 87:338–344. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hirokawa T, Arimasu Y, Chiba T, Fujiwara M
and Kamma H: Clinicopathological significance of the single
nucleotide polymorphism, rs2853669 within the TERT promoter in
papillary thyroid carcinoma. Pathol Int. 70:217–223. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hirokawa T, Arimasu Y, Nakazato Y, Chiba
T, Fujiwara M and Kamma H: Effect of single-nucleotide polymorphism
in TERT promoter on follicular thyroid tumor development. Pathol
Int. 70:210–216. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gouda MA, Nelson BE, Buschhorn L, Wahida A
and Subbiah V: Tumor-Agnostic precision medicine from the AACR
GENIE database: Clinical implications. Clin Cancer Res.
29:2753–2760. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kamma H, Kameyama K, Kondo T, Imamura Y,
Nakashima M, Chiba T and Hirokawa M: Pathological diagnosis of
general rules for the description of thyroid cancer by Japanese
Society of Thyroid Pathology and Japan Association of Endocrine
Surgery. Endocr J. 69:139–154. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kumagai S, Togashi Y, Kamada T, Sugiyama
E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y,
Matsui S, et al: The PD-1 expression balance between effector and
regulatory T cells predicts the clinical efficacy of PD-1 blockade
therapies. Nat Immunol. 21:1346–1358. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Marabelle A, Fakih M, Lopez J, Shah M,
Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin
JA, Miller WH Jr, et al: Association of tumour mutational burden
with outcomes in patients with advanced solid tumours treated with
pembrolizumab: prospective biomarker analysis of the multicohort,
open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21:1353–1365.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Akagi K, Oki E, Taniguchi H, Nakatani K,
Aoki D, Kuwata T and Yoshino T: Real-world data on microsatellite
instability status in various unresectable or metastatic solid
tumors. Cancer Sci. 112:1105–1113. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lawrence MS, Stojanov P, Polak P, Kryukov
GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH,
Roberts SA, et al: Mutational heterogeneity in cancer and the
search for new cancer-associated genes. Nature. 499:214–218. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bertol BC, Massaro JD, Debortoli G, Santos
ALP, de Araújo JNG, Giorgenon TMV, Silva MC, de Figueiredo-Feitosa
NL, Collares CVA, de Freitas LCC, et al: BRAF, TERT and HLA-G
status in the papillary thyroid carcinoma: A clinicopathological
association study. Int J Mol Sci. 24:124592023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Muzza M, Colombo C, Rossi S, Tosi D,
Cirello V, Perrino M, De Leo S, Magnani E, Pignatti E, Vigo B, et
al: Telomerase in differentiated thyroid cancer: Promoter
mutations, expression, and localization. Mol Cell Endocrinol.
399:288–295. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sherry ST, Ward MH, Kholodov M, Baker J,
Phan L, Smigielski EM and Sirotkin K: dbSNP: the NCBI database of
genetic variation. Nucleic Acids Res. 29:308–311. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
1000 Genomes Project Consortium, . Auton
A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini
JL, McCarthy S, McVean GA and Abecasis GR: A global reference for
human genetic variation. Nature. 526:68–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Spiegl-Kreinecker S, Lötsch D, Ghanim B,
Pirker C, Mohr T, Laaber M, Weis S, Olschowski A, Webersinke G,
Pichler J and Berger W: Prognostic quality of activating TERT
promoter mutations in glioblastoma: Interaction with the rs2853669
polymorphism and patient age at diagnosis. Neuro Oncol.
17:1231–1240. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Landa I, Ganly I, Chan TA, Mitsutake N,
Matsuse M, Ibrahimpasic T, Ghossein RA and Fagin JA: Frequent
somatic TERT promoter mutations in thyroid cancer: Higher
prevalence in advanced forms of the disease. J Clin Endocrinol
Metab. 98:E1562–E1566. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu T, Wang N, Cao J, Sofiadis A, Dinets
A, Zedenius J, Larsson C and Xu D: The age- and shorter
telomere-dependent TERT promoter mutation in follicular thyroid
cell-derived carcinomas. Oncogene. 33:4978–4984. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Vuong HG, Altibi AMA, Duong UNP and
Hassell L: Prognostic implication of BRAF and TERT promoter
mutation combination in papillary thyroid carcinoma-A
meta-analysis. Clin Endocrinol (Oxf). 87:411–417. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Soares P, Celestino R, Melo M, Fonseca E
and Sobrinho-Simões M: Prognostic biomarkers in thyroid cancer.
Virchows Arch. 464:333–346. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
da Silva RC, de Paula HS, Leal CB, Cunha
BC, de Paula EC, Alencar RC, Meneghini AJ, Silva AM, Gontijo AP,
Wastowski IJ and Saddi VA: BRAF overexpression is associated with
BRAF V600E mutation in papillary thyroid carcinomas. Genet Mol Res.
14:5065–5075. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Feng L, Li M, Zhang QP, Piao ZA, Wang ZH
and Lv S: Utility of BRAF protein overexpression in predicting the
metastasis potential of papillary thyroid carcinoma. Oncol Lett.
2:59–63. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jin L, Chen E, Dong S, Cai Y, Zhang X,
Zhou Y, Zeng R, Yang F, Pan C, Liu Y, et al: BRAF and TERT promoter
mutations in the aggressiveness of papillary thyroid carcinoma: a
study of 653 patients. Oncotarget. 7:18346–18355. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Nakao T, Matsuse M, Saenko V, Rogounovitch
T, Tanaka A, Suzuki K, Higuchi M, Sasai H, Sano T, Hirokawa M, et
al: Preoperative detection of the TERT promoter mutations in
papillary thyroid carcinomas. Clin Endocrinol (Oxf). 95:790–799.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Subbiah V, Kreitman RJ, Wainberg ZA, Cho
JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME,
Urbanowitz G, et al: Dabrafenib and trametinib treatment in
patients with locally advanced or metastatic BRAF V600-mutant
anaplastic thyroid cancer. J Clin Oncol. 36:7–13. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bible KC, Kebebew E, Brierley J, Brito JP,
Cabanillas ME, Clark TJ, Di Cristofano A, Foote R, Giordano T,
Kasperbauer J, et al: 2021 American Thyroid Association guidelines
for management of patients with anaplastic thyroid cancer. Thyroid.
31:337–386. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Nakano T, Fujimoto K, Tomiyama A,
Takahashi M, Achiha T, Arita H, Kawauchi D, Yasukawa M, Masutomi K,
Kondo A, et al: Eribulin prolongs survival in an orthotopic
xenograft mouse model of malignant meningioma. Cancer Sci.
113:697–708. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mochizuki T, Ikegami M and Akiyama T:
Factors predictive of second-line chemotherapy in soft tissue
sarcoma: An analysis of the National Genomic Profiling Database.
Cancer Sci. 115:575–588. 2024. View Article : Google Scholar : PubMed/NCBI
|
